Pharmacotherapy of Peptic Ulcer

Pharmacotherapy of Peptic Ulcer

Drugs that reduce gastric acidity, protect the mucosa and eradicate H. pylori

1

Introduction

Peptic ulcer is a break in the lining of the stomach or duodenum caused by an imbalance between aggressive factors and the protective mechanisms of the mucosa.

Important Causes

  • Helicobacter pylori: A major cause of chronic gastritis and peptic ulcer disease.
  • NSAIDs: Reduce protective prostaglandin synthesis and weaken the gastric mucosal barrier.
  • Excessive acid secretion and other factors may contribute to ulcer formation.

Protective Mechanisms

  • Mucus and bicarbonate form a protective surface barrier.
  • Prostaglandins support mucus and bicarbonate secretion.
  • Good mucosal blood flow helps maintain tissue health.
  • Rapid repair and replacement of epithelial cells help heal injury.

Principles of Treatment

  • Reduce gastric acid secretion.
  • Eradicate H. pylori when infection is confirmed.
  • Protect the ulcer surface and promote healing.
  • Avoid or minimise ulcer-producing medicines such as NSAIDs when possible.
2

Drugs that Reduce Acid Secretion

H2-Receptor Blockers

Examples: Famotidine, cimetidine and nizatidine.

  • Competitively block histamine H2 receptors on gastric parietal cells.
  • Reduce basal and stimulated gastric acid secretion.
  • Used in selected cases of peptic ulcer, gastro-oesophageal reflux and acid-related disorders.
Cimetidine: Inhibits several cytochrome P450 enzymes and can cause drug interactions. It may also produce anti-androgenic effects such as gynaecomastia and sexual dysfunction.

Famotidine has fewer drug interactions and lacks the anti-androgenic effects associated with cimetidine.

Proton Pump Inhibitors (PPIs)

Examples: Omeprazole, pantoprazole, esomeprazole, lansoprazole and rabeprazole.

  • Inhibit the gastric H+/K+ ATPase enzyme, also called the proton pump.
  • Block the final step of acid secretion and produce powerful acid suppression.
  • They are commonly taken before meals according to the prescribed preparation and schedule.

Therapeutic Uses of PPIs

  • Healing of gastric and duodenal ulcers.
  • NSAID-associated ulcers and prevention in selected high-risk patients.
  • Gastro-oesophageal reflux disease, especially when oesophagitis is present.
  • Zollinger–Ellison syndrome.
  • Part of combination treatment for H. pylori infection.
Adverse effects: Headache, abdominal discomfort, diarrhoea and, with prolonged use in susceptible patients, reduced vitamin B12 or magnesium levels and increased risk of certain intestinal infections.

Other Acid-Reducing Drugs

  • Anticholinergics: Reduce gastric secretion but are limited by adverse effects such as dry mouth, blurred vision and urinary retention.
  • Misoprostol: A prostaglandin analogue that reduces acid secretion and increases mucus and bicarbonate. It can prevent NSAID-induced ulcers but is contraindicated in pregnancy because it can cause uterine contractions.
3

Antacids

Antacids are weak bases that neutralise hydrochloric acid already present in the stomach. They provide symptomatic relief but do not directly stop acid production.

Classification

Systemic antacidSodium bicarbonate. It is absorbed and may cause metabolic alkalosis and sodium overload.
Non-systemic antacidsMagnesium hydroxide, aluminium hydroxide and magnesium trisilicate. They are poorly absorbed.

Adverse Effects

  • Magnesium salts: Diarrhoea; use cautiously in renal impairment.
  • Aluminium salts: Constipation and, with prolonged use, phosphate depletion.
  • Sodium bicarbonate: Belching, sodium retention and metabolic alkalosis.

Why Magnesium and Aluminium Are Combined

  • Magnesium acts relatively quickly, while aluminium provides a slower effect.
  • Magnesium may cause diarrhoea, whereas aluminium may cause constipation.
  • Combining them can balance bowel effects and improve tolerability.
Drug interactions: Antacids can reduce the absorption of medicines such as tetracyclines, iron and some other drugs. Separate administration according to the medicine’s instructions.
4

Ulcer Protective Drugs

Sucralfate

  • Forms a protective coating over the ulcer surface and acts as a physical barrier against acid and pepsin.
  • Adheres preferentially to damaged tissue and supports mucosal protection.
  • Usually administered before meals on an empty stomach as prescribed.
  • May interfere with absorption of other medicines, so doses should be separated.

Bismuth Compounds

Examples include colloidal bismuth subcitrate and bismuth subsalicylate.

  • Coat the ulcer surface and increase mucosal defence.
  • Have activity against H. pylori and are used in selected eradication regimens.
  • May cause darkening of the tongue and stools.

Carbenoxolone

It promotes mucus production and mucosal healing but is rarely used because of steroid-like adverse effects.

  • May cause sodium and water retention, oedema and hypertension.
  • May reduce potassium levels.
5

H. pylori Eradication

H. pylori is a gram-negative bacterium that survives in the stomach and damages the mucosal defence system. Confirmed infection in patients with peptic ulcer disease should be treated.

Drugs Used

  • Proton pump inhibitor.
  • Amoxicillin.
  • Clarithromycin, metronidazole or tetracycline, depending on the selected regimen and local resistance patterns.
  • Bismuth may be included in appropriate combination regimens.
Important: Single-drug treatment is unsuitable because resistance develops and eradication rates are poor. Use a complete, guideline-based combination regimen selected by a clinician.

Confirmation of Eradication

Successful treatment may be checked with a urea breath test or stool antigen test at the recommended time after therapy. Acid-suppressing medicines may need to be withheld before testing as advised by the clinician.

Clinical point: After successful eradication, the risk of ulcer recurrence falls substantially, unless another cause such as continued NSAID use remains.